4591.TSE · Ribomic Inc

-

Please sign in to comment on 4591.TSE

1 Comment

Admin

4 years ago

Ribomic Inc is currently in a long term downtrend where the price is trading 14.6% below its 200 day moving average.

From a valuation standpoint, the stock is 17.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 83.1.

Ribomic Inc's total revenue sank by 2.6% to $2M since the same quarter in the previous year.

Its net income has dropped by 4.7% to $-265M since the same quarter in the previous year.

Based on the above factors, Ribomic Inc gets an overall score of 0/5.

Exchange	TSE
CurrencyCode	JPY
ISIN	JP3974850004
Sector	Healthcare
Industry	Biotechnology

Market Cap	4B
PE Ratio	None
Target Price	None
Beta	0.6
Dividend Yield	None

ABOUT

Ribomic Inc

Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.

4591.TSE · Ribomic Inc

-

Ribomic Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Ribomic Inc using a moving average strategy